Tivozanib

Drug Profile

Tivozanib

Alternative Names: ASP 4130; AV-951; Fotivda; Kil8951; KRN-951; Tivopath; Tivozanib hydrochloride monohydrate

Latest Information Update: 30 Jun 2017

Price : $50

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AVEO Oncology; EUSA Pharma; Institute Gustave-Roussy; Kyowa Hakko Kirin; Pharmstandard
  • Class Antineoplastics; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preregistration Renal cell carcinoma
  • Phase I Solid tumours
  • Suspended Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 23 Jun 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of tivozanib for Renal Cell Carcinoma (Late-stage disease, Monotherapy, First-line therapy, Second-line therapy or greater) in the European Union
  • 20 Jun 2017 AVEO oncology expects the European regulatory decision on submitted MAA of tivizanib for Renal cell carcinoma (First-line therapy, Late-stage disease, Monotherapy) in Q1-2018
  • 08 Jun 2017 Phase-II clinical trials in Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease) in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top